PMEF
CMPX icon

Point72 Middle East FZE’s Compass Therapeutics CMPX Stock Holding History

Point72 Middle East FZE’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,497
Closed -$47.4K – 1609
2023
Q1 		$47.4K Buy
+14,497
New +$56.9K ﹤0.01% 1277

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Point72 Middle East FZE's CMPX Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Compass Therapeutics (CMPX) in Q2 2023, closing a stake of 14,497 shares — an estimated $47.4K sold.

Point72 Middle East FZE first reported a position in CMPX in Q1 2023 and held it in 1 quarter. The position peaked at $47.4K in Q1 2023. 73 funds tracked by Wall St. Rank hold CMPX as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Compass Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 14,497 Compass Therapeutics shares in Q2 2023, an estimated $47.4K.
  • Point72 Middle East FZE first reported a position in Compass Therapeutics in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Compass Therapeutics position peaked at $47.4K in Q1 2023.
  • 73 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.